ARGX 113

Drug Profile

ARGX 113

Alternative Names: ARGX-113

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator arGEN-X
  • Developer argenx
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Myasthenia gravis
  • Preclinical Immune thrombocytopenic purpura

Most Recent Events

  • 15 Mar 2017 argenx plans a phase I trial in volunteers [SC]
  • 15 Mar 2017 argenx plans a phase II proof-of-concept trial for Immune thrombocytopenic purpura
  • 08 Nov 2016 Phase-II clinical trials in Myasthenia gravis in Netherlands, Netherlands, Sweden (unspecified route) after November 2016 (EudraCT2016-002938-73)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top